Publications by authors named "A Claxton"

Claim this Profile
L
Long-term efficacy, safety, and tolerability of xanomeline and trospium chloride in schizophrenia: A 52-week, open-label trial (EMERGENT-5).
Inder Kaul, Amy Claxton, Soumya Chaturvedi, Tejendra Patel, Hsiuanlin Wu

Schizophr Res· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unmet Needs of Effective Advanced Systemic Therapies in Moderate-to-Severe Atopic Dermatitis Patients in the TARGET-DERM AD Registry.
Dawn Z Eichenfield, Keith D Knapp, Ami Claxton, Breda Munoz, Julie M Crawford

Dermatitis· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials.
Inder Kaul, Sharon Sawchak, Amy Claxton, Colin Sauder, Howard H Hassman

Schizophrenia (Heidelb)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capturing changes in social functioning and positive affect using ecological momentary assessment during a 12-month trial of xanomeline and trospium chloride in schizophrenia.
Philip D Harvey, Inder Kaul, Soumya Chataverdi, Tej Patel, Amy Claxton

Schizophr Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the 5-Week, Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials.
Inder Kaul, Amy Claxton, Sharon Sawchak, Colin Sauder, Stephen K Brannan

J Clin Psychiatry· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis